Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

Sneha Gullapalli, Jordi Remon*, Lizza El Hendriks, Gilberto Lopes

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Web of Science)

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono - therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

Original languageEnglish
Pages (from-to)6885-6896
Number of pages12
JournalOncotargets and Therapy
Volume13
DOIs
Publication statusPublished - 14 Jul 2020

Keywords

  • durvalumab
  • non-small cell lung cancer
  • PACIFIC
  • rechallenge
  • MYSTIC
  • PLATINUM-BASED CHEMOTHERAPY
  • STAGE-III NSCLC
  • CHEMORADIOTHERAPY REGIMEN
  • PHASE-III
  • PEMBROLIZUMAB
  • NIVOLUMAB
  • EFFICACY
  • OUTCOMES
  • 1ST-LINE
  • SAFETY

Cite this